Literature DB >> 26243861

ERBB2 emerges as a new target for colorectal cancer.

Eirini Pectasides1, Adam J Bass2.   

Abstract

ERBB2 mutations and amplifications are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefit from ERBB2-directed therapy. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26243861      PMCID： PMC4527096          DOI： 10.1158/2159-8290.CD-15-0730

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  7 in total

1.  Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.

Authors:  Michael Kloth; Vanessa Ruesseler; Christoph Engel; Katharina Koenig; Martin Peifer; Erika Mariotti; Helen Kuenstlinger; Alexandra Florin; Ursula Rommerscheidt-Fuss; Ulrike Koitzsch; Claudia Wodtke; Frank Ueckeroth; Stefanie Holzapfel; Stefan Aretz; Peter Propping; Markus Loeffler; Sabine Merkelbach-Bruse; Margarete Odenthal; Nicolaus Friedrichs; Lukas Carl Heukamp; Thomas Zander; Reinhard Buettner
Journal:  Gut       Date:  2015-04-28       Impact factor: 23.059

2.  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

Authors:  Heidi Greulich; Bethany Kaplan; Philipp Mertins; Tzu-Hsiu Chen; Kumiko E Tanaka; Cai-Hong Yun; Xiaohong Zhang; Se-Hoon Lee; Jeonghee Cho; Lauren Ambrogio; Rachel Liao; Marcin Imielinski; Shantanu Banerji; Alice H Berger; Michael S Lawrence; Jinghui Zhang; Nam H Pho; Sarah R Walker; Wendy Winckler; Gad Getz; David Frank; William C Hahn; Michael J Eck; D R Mani; Jacob D Jaffe; Steven A Carr; Kwok-Kin Wong; Matthew Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

3.  Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

Authors:  Kimio Yonesaka; Kreshnik Zejnullahu; Isamu Okamoto; Taroh Satoh; Federico Cappuzzo; John Souglakos; Dalia Ercan; Andrew Rogers; Massimo Roncalli; Masayuki Takeda; Yasuhito Fujisaka; Juliet Philips; Toshio Shimizu; Osamu Maenishi; Yonggon Cho; Jason Sun; Annarita Destro; Koichi Taira; Koji Takeda; Takafumi Okabe; Jeffrey Swanson; Hiroyuki Itoh; Minoru Takada; Eugene Lifshits; Kiyotaka Okuno; Jeffrey A Engelman; Ramesh A Shivdasani; Kazuto Nishio; Masahiro Fukuoka; Marileila Varella-Garcia; Kazuhiko Nakagawa; Pasi A Jänne
Journal:  Sci Transl Med       Date:  2011-09-07       Impact factor: 17.956

4.  Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Authors:  Ron Bose; Shyam M Kavuri; Adam C Searleman; Wei Shen; Dong Shen; Daniel C Koboldt; John Monsey; Nicholas Goel; Adam B Aronson; Shunqiang Li; Cynthia X Ma; Li Ding; Elaine R Mardis; Matthew J Ellis
Journal:  Cancer Discov       Date:  2012-12-07       Impact factor: 39.397

5.  HER2 activating mutations are targets for colorectal cancer treatment.

Authors:  Shyam M Kavuri; Naveen Jain; Francesco Galimi; Francesca Cottino; Simonetta M Leto; Giorgia Migliardi; Adam C Searleman; Wei Shen; John Monsey; Livio Trusolino; Samuel A Jacobs; Andrea Bertotti; Ron Bose
Journal:  Cancer Discov       Date:  2015-08       Impact factor: 39.397

6.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Authors:  Andrea Bertotti; Giorgia Migliardi; Francesco Galimi; Francesco Sassi; Davide Torti; Claudio Isella; Davide Corà; Federica Di Nicolantonio; Michela Buscarino; Consalvo Petti; Dario Ribero; Nadia Russolillo; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Luca Molinaro; Emanuele Valtorta; Andrea Sartore-Bianchi; Mauro Risio; Lorenzo Capussotti; Marcello Gambacorta; Salvatore Siena; Enzo Medico; Anna Sapino; Silvia Marsoni; Paolo M Comoglio; Alberto Bardelli; Livio Trusolino
Journal:  Cancer Discov       Date:  2011-09-02       Impact factor: 39.397

7.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962
  7 in total
  7 in total

1.  Gene-Mutation-Based Algorithm for Prediction of Treatment Response in Colorectal Cancer Patients.

Authors:  Heather Johnson; Zahra El-Schich; Amjad Ali; Xuhui Zhang; Athanasios Simoulis; Anette Gjörloff Wingren; Jenny L Persson
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

2.  Multi-region and single-cell sequencing reveal variable genomic heterogeneity in rectal cancer.

Authors:  Mingshan Liu; Yang Liu; Jiabo Di; Zhe Su; Hong Yang; Beihai Jiang; Zaozao Wang; Meng Zhuang; Fan Bai; Xiangqian Su
Journal:  BMC Cancer       Date:  2017-11-23       Impact factor: 4.430

3.  A robust targeted sequencing approach for low input and variable quality DNA from clinical samples.

Authors:  Austin P So; Anna Vilborg; Yosr Bouhlal; Ryan T Koehler; Susan M Grimes; Yannick Pouliot; Daniel Mendoza; Janet Ziegle; Jason Stein; Federico Goodsaid; Michael Y Lucero; Francisco M De La Vega; Hanlee P Ji
Journal:  NPJ Genom Med       Date:  2018-01-15       Impact factor: 8.617

4.  Uncovering the action mechanism of homoharringtonine against colorectal cancer by using network pharmacology and experimental evaluation.

Authors:  Muwen Qu; Junyi Li; Lingling Yuan
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 5.  HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.

Authors:  Valentina Fanotto; Elena Ongaro; Karim Rihawi; Antonio Avallone; Nicola Silvestris; Lorenzo Fornaro; Enrico Vasile; Lorenzo Antonuzzo; Francesco Leone; Gerardo Rosati; Francesco Giuliani; Roberto Bordonaro; Mario Scartozzi; Giovanna De Maglio; Francesca V Negri; Gianpiero Fasola; Giuseppe Aprile
Journal:  Oncotarget       Date:  2016-10-18

6.  Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications.

Authors:  Ecaterina E Ileana Dumbrava; Kavitha Balaji; Kanwal Raghav; Kenneth Hess; Milind Javle; Mariela Blum-Murphy; Jaffer Ajani; Scott Kopetz; Russell Broaddus; Mark Routbort; Mehmet Demirhan; Xiaofeng Zheng; Shubham Pant; Apostolia M Tsimberidou; Vivek Subbiah; David S Hong; Jordi Rodon; Kenna M Shaw; Sarina A Piha-Paul; Funda Meric-Bernstam
Journal:  JCO Precis Oncol       Date:  2019-10-21

7.  Development and Validation of a Targeted 'Liquid' NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer.

Authors:  Myrto Kastrisiou; George Zarkavelis; Anastasia Kougioumtzi; Prodromos Sakaloglou; Charilaos Kostoulas; Ioannis Georgiou; Anna Batistatou; George Pentheroudakis; Angeliki Magklara
Journal:  Diagnostics (Basel)       Date:  2021-12-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.